NASDAQ:FHTX Foghorn Therapeutics (FHTX) Stock Price, News & Analysis $6.76 +0.24 (+3.68%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.49▼$6.9350-Day Range$4.80▼$6.7652-Week Range$2.70▼$9.97Volume91,063 shsAverage Volume129,135 shsMarket Capitalization$287.91 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Foghorn Therapeutics alerts: Email Address Foghorn Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside92.3% Upside$13.00 Price TargetShort InterestBearish4.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.20) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector718th out of 936 stocksPharmaceutical Preparations Industry335th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingFoghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFoghorn Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Foghorn Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.01% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Foghorn Therapeutics has recently increased by 15.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFoghorn Therapeutics does not currently pay a dividend.Dividend GrowthFoghorn Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FHTX. Previous Next 2.5 News and Social Media Coverage News SentimentFoghorn Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Foghorn Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.07% of the stock of Foghorn Therapeutics is held by insiders.Percentage Held by Institutions61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Foghorn Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Foghorn Therapeutics are expected to grow in the coming year, from ($2.20) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foghorn Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foghorn Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Foghorn Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Foghorn Therapeutics Stock (NASDAQ:FHTX)Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FHTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FHTX Stock News HeadlinesMay 28, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Upcoming Investor Conferences in JuneMay 22, 2024 | globenewswire.comFoghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 20, 2024 | msn.comFoghorn prices $110M mixed-shelf registered direct offeringMay 20, 2024 | globenewswire.comFoghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded WarrantsMay 9, 2024 | finance.yahoo.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price TargetMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Foghorn Therapeutics with Promising AML Drug Pipeline and Broad Market PotentialMay 7, 2024 | finance.yahoo.comFoghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 6, 2024 | finanznachrichten.deFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate UpdateMay 6, 2024 | finance.yahoo.comFoghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...May 6, 2024 | investorplace.comFHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comFoghorn Therapeutics Provides First Quarter 2024 Financial and Corporate UpdateApril 18, 2024 | bizjournals.comPetri Dish: Non-viral vector startup launch; Foghorn’s new CFOApril 16, 2024 | marketwatch.comFoghorn Therapeutics Taps Kristian Humer as Finance ChiefApril 16, 2024 | globenewswire.comFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerApril 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)April 10, 2024 | markets.businessinsider.comFoghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic AlliancesSee More Headlines Receive FHTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FHTX CUSIPN/A CIK1822462 Webfoghorntx.com Phone617-586-3100FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$20.00 Low Stock Price Target$6.00 Potential Upside/Downside+87.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,430,000.00 Net Margins-274.23% Pretax Margin-263.42% Return on EquityN/A Return on Assets-31.14% Debt Debt-to-Equity RatioN/A Current Ratio4.06 Quick Ratio4.06 Sales & Book Value Annual Sales$34.15 million Price / Sales8.64 Cash FlowN/A Price / Cash FlowN/A Book Value($1.83) per share Price / Book-3.79Miscellaneous Outstanding Shares42,590,000Free Float38,723,000Market Cap$295.15 million OptionableOptionable Beta3.10 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Adrian H. B. Gottschalk (Age 48)President, CEO & Director Comp: $784.65kDr. Steven F. Bellon Ph.D. (Age 59)Chief Scientific Officer Comp: $572.6kDr. Alfonso Quintas Cardama M.D. (Age 53)Chief Medical Officer Comp: $300.16kDr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory BoardMr. Kristian Humer M.B.A. (Age 48)Chief Financial Officer Ms. Karin HellsvikVP, Corporate Affairs & Investor RelationsMr. Michael J. LaCascia (Age 59)Chief Legal Officer Comp: $565.5kMr. Saurabh Sewak Ph.D.Vice President of Corporate DevelopmentMr. Carlos Costa (Age 51)Chief People Officer Ms. Fanny Cavalie (Age 46)Chief Strategy & Business Operations Officer More ExecutivesKey CompetitorsZIOPHARM OncologyNASDAQ:ZIOPInozyme PharmaNASDAQ:INZYC4 TherapeuticsNASDAQ:CCCCTango TherapeuticsNASDAQ:TNGXBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 18,664 shares on 7/26/2024Ownership: 0.187%Raymond James & AssociatesBought 107,967 shares on 7/19/2024Ownership: 5.491%Jacobs Levy Equity Management Inc.Bought 108,700 shares on 5/16/2024Ownership: 0.508%Vanguard Group Inc.Bought 77,380 shares on 5/10/2024Ownership: 2.590%Acadian Asset Management LLCBought 42,367 shares on 5/10/2024Ownership: 0.100%View All Insider TransactionsView All Institutional Transactions FHTX Stock Analysis - Frequently Asked Questions How have FHTX shares performed this year? Foghorn Therapeutics' stock was trading at $6.45 at the beginning of the year. Since then, FHTX shares have increased by 4.8% and is now trading at $6.76. View the best growth stocks for 2024 here. How were Foghorn Therapeutics' earnings last quarter? Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings results on Monday, May, 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.04. The business had revenue of $5.05 million for the quarter, compared to the consensus estimate of $7.53 million. When did Foghorn Therapeutics IPO? Foghorn Therapeutics (FHTX) raised $120 million in an IPO on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Foghorn Therapeutics' major shareholders? Top institutional shareholders of Foghorn Therapeutics include Raymond James & Associates (5.49%) and Bank of New York Mellon Corp (0.19%). View institutional ownership trends. How do I buy shares of Foghorn Therapeutics? Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FHTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FHTX Stock Alerts